Cover Image
市場調查報告書

老年衰弱症- 開發中產品分析

Age Related Functional Decline - Pipeline Review, H2 2014

出版商 Global Markets Direct 商品編碼 321920
出版日期 內容資訊 英文 27 Pages
訂單完成後即時交付
價格
Back to Top
老年衰弱症- 開發中產品分析 Age Related Functional Decline - Pipeline Review, H2 2014
出版日期: 2014年12月31日 內容資訊: 英文 27 Pages
簡介

老年衰弱症是由於年紀大造成的身體功能喪失。有視力減退、肌肉退化、白內障、青光眼、骨質疏鬆症、平衡感低落、記憶及腦功能衰退等。

本報告提供老年衰弱症的治療藥開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

老年衰弱症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/實驗室

開發中產品的概要

  • 初期階段的產品

開發中的產品:各企業

調查中的產品:各大學/實驗室

治療藥的開發企業

  • Chronos Therapeutics Limited 13
  • TAmiRNA GmbH 14

治療藥的評估

  • 單獨療法產品
  • 聯合治療的產品
  • 標的別
  • 各作用機制
  • 各分子類型

藥物簡介

  • CHR-1
  • CHR-3
  • Drug for Frailty Disease
  • metformin + sirolimus
  • Small Molecules for Age Related Diseases

最新的開發中產品資訊

開發暫停中的計劃

附錄

圖表

目錄
Product Code: GMDHC5941IDB

Summary

Global Markets Direct's, 'Age Related Functional Decline - Pipeline Review, H2 2014', provides an overview of the Age Related Functional Decline's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Age Related Functional Decline, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Age Related Functional Decline and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Age Related Functional Decline
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Age Related Functional Decline and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Age Related Functional Decline products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Age Related Functional Decline pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Age Related Functional Decline
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Age Related Functional Decline pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Age Related Functional Decline Overview
  • Therapeutics Development
    • Pipeline Products for Age Related Functional Decline - Overview
    • Pipeline Products for Age Related Functional Decline - Comparative Analysis
  • Age Related Functional Decline - Therapeutics under Development by Companies
  • Age Related Functional Decline - Therapeutics under Investigation by Universities/Institutes
  • Age Related Functional Decline - Pipeline Products Glance
    • Early Stage Products
  • Age Related Functional Decline - Products under Development by Companies
  • Age Related Functional Decline - Products under Investigation by Universities/Institutes
  • Age Related Functional Decline - Companies Involved in Therapeutics Development
    • Chronos Therapeutics Limited
    • TAmiRNA GmbH
  • Age Related Functional Decline - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Molecule Type
  • Drug Profiles
    • CHR-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CHR-3 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug for Frailty Disease - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • metformin + sirolimus - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Age Related Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Age Related Functional Decline - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Age Related Functional Decline, H2 2014
  • Number of Products under Development for Age Related Functional Decline - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Investigation by Universities/Institutes, H2 2014
  • Age Related Functional Decline - Pipeline by Chronos Therapeutics Limited, H2 2014
  • Age Related Functional Decline - Pipeline by TAmiRNA GmbH, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Assessment by Combination Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Age Related Functional Decline - Dormant Projects, H2 2014

List of Figures

  • Number of Products under Development for Age Related Functional Decline, H2 2014
  • Number of Products under Development for Age Related Functional Decline - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
Back to Top